Chronic myelogenous leukemia: biology and therapy
S Faderl, M Talpaz, Z Estrov… - Annals of internal …, 1999 - acpjournals.org
Chronic myelogenous leukemia is a myeloproliferative disorder. It is characterized by a
biphasic or triphasic clinical course in which a benign chronic phase is followed by …
biphasic or triphasic clinical course in which a benign chronic phase is followed by …
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz, R Hehlmann, A Quintas-Cardama, J Mercer… - Leukemia, 2013 - nature.com
Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
Chronic myelogenous leukemia: a review
JE Cortes, M Talpaz, H Kantarjian - The American journal of medicine, 1996 - Elsevier
Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder with an
initially chronic course lasting for 3–5 years. It eventually transforms into accelerated and …
initially chronic course lasting for 3–5 years. It eventually transforms into accelerated and …
[PDF][PDF] Treatment of chronic myelogenous leukemia: current status and investigational options
HM Kantarjian, S O'Brien, P Anderlini, M Talpaz - Blood, 1996 - Citeseer
(Ph)-positive chronic myelogenous leukemia (CML) have matured. These include single and
multi-institutional programs with allogeneic bone marrow transplantation (BMT), interferon-a …
multi-institutional programs with allogeneic bone marrow transplantation (BMT), interferon-a …
Chronic myelogenous leukemia: a review and update of therapeutic strategies
G Garcia-Manero, S Faderl, S O'Brien… - …, 2003 - mdanderson.elsevierpure.com
The prognosis of patients with chronic myelogenous leukemia (CML) has significantly
improved over the last 20 years. Whereas the median survival durations were 4-5 years in …
improved over the last 20 years. Whereas the median survival durations were 4-5 years in …
The interferon-alpha revival in CML
M Talpaz, J Mercer, R Hehlmann - Annals of hematology, 2015 - Springer
Interferon-alpha (IFNα) was once the standard of frontline treatment for chronic myeloid
leukemia (CML). Its pleiotropic mechanism of action in CML includes immune activation and …
leukemia (CML). Its pleiotropic mechanism of action in CML includes immune activation and …
The role of interferon-alpha in the treatment of chronic myeloid leukemia
LA Kujawski, M Talpaz - Cytokine & growth factor reviews, 2007 - Elsevier
Biological agents have long been used in the treatment of cancer, and interferon-alpha was
the first human cytokine to be widely studied in this setting. Chronic myeloid leukemia (CML) …
the first human cytokine to be widely studied in this setting. Chronic myeloid leukemia (CML) …
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine
HM Kantarjian, S O'Brien, TL Smith, MB Rios… - Journal of Clinical …, 1999 - ascopubs.org
PURPOSE: To evaluate the efficacy of the combination of interferon alpha (IFN-α) and daily
low-dose cytarabine (ara-C) in the treatment of patients with early chronic-phase chronic …
low-dose cytarabine (ara-C) in the treatment of patients with early chronic-phase chronic …
Second-generation interferons for cancer: clinical targets
EC Borden, D Lindner, R Dreicer, M Hussein… - Seminars in cancer …, 2000 - Elsevier
IFNs were the first new therapeutic products resulting from recombinant DNA technology.
IFNs were also the first human proteins effective in cancer treatment. There is however much …
IFNs were also the first human proteins effective in cancer treatment. There is however much …
Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy
HM Kantarjian, FJ Giles, SM O'Brien… - … /oncology clinics of North …, 1998 - Elsevier
The prognosis for patients with chronic myelogenous leukemia (CML) has changed
markedly since 1856, when the use of arsenicals (Fowler's solution) was first advocated in …
markedly since 1856, when the use of arsenicals (Fowler's solution) was first advocated in …